Mayo Clinic Just Proved What Cardiologists Really Need

Pulmonary hypertension kills quietly. According to a Mayo Clinic-sourced retrospective study published in Pulmonary Circulation, patients diagnosed early had a 73% five-year survival rate — compared to just 31% for those diagnosed late. That gap is not a footnote. It is the entire argument for why diagnostic timing matters.

On April 28, 2026, CorVista Health announced a prospective research collaboration with Mayo Clinic to evaluate whether its FDA-cleared, non-invasive CorVista-PH test can improve PH detection and referral when used alongside current standard-of-care approaches, according to Business Wire.

This article breaks down what CorVista actually does, what the Mayo Clinic research means in clinical terms, and whether it deserves a place in your practice's diagnostic workflow.

What Is CorVista and How Does It Work?

CorVista is a non-invasive, point-of-care cardiovascular diagnostic platform that uses machine learning to analyze physiologic signals — no radiation, no fasting, no specialist required to operate it.

The signal capture takes approximately 3.5 minutes with the patient at rest, and full multi-condition results are delivered within a single clinical visit. According to CorVista Health, the platform currently carries two FDA clearances:

• Coronary artery disease (CAD) — cleared September 2023, with 99% negative predictive value and performance comparable to CCTA for ruling out significant disease
• Pulmonary hypertension (PH) — cleared April 2024, making it the first FDA-cleared, machine-learned point-of-care test for indicating elevated mean pulmonary artery pressure (mPAP)

The PH Add-On earned FDA Breakthrough Device Designation and was validated in the IDENTIFY PH study across 462 symptomatic patients at 18 U.S. sites. According to Globe Newswire, the algorithm demonstrated 82% sensitivity, 92% specificity, and a negative predictive value exceeding 99% — consistent across sex, age, BMI, and comorbidities including diabetes and COPD.

For practice administrators, that last detail matters operationally: performance that holds across your actual patient mix is what makes a diagnostic tool deployable, not just publishable.

The Mayo Clinic Connection: What the Research Actually Shows

The Mayo Clinic partnership announced on April 28, 2026 is not a press release credential — it is a prospective observational study designed to evaluate whether the CorVista-PH test improves detection and referral of patients with suspected pulmonary hypertension alongside current standard approaches. That is a different level of scrutiny than a marketing endorsement.

What makes this partnership meaningful is the evidence stack it caps. In the 12 months before the collaboration was announced, CorVista built a compounding credibility trail:

• The IDENTIFY PH validation study — 462 symptomatic patients, 18 U.S. clinical sites, blinded design, published in the European Respiratory Journal Open Research (May 2025) — validated algorithm performance on a dataset independent of development data
• A real-world case series published in the Journal of the American College of Cardiology (September 2025) confirmed PH in all four patients via right heart catheterization — including one who had multiple prior TTEs return negative
• ACC.26 data (March 2026) showed 90% sensitivity and 99% negative predictive value for ischemia detection across sex, age, and BMI

For practice decision-makers, this sequence matters. Peer review, real-world case confirmation, major conference presentation, then institutional co-validation. Each step addresses a different objection a cautious clinician would raise.

One disclosure worth noting: according to Pulmonary Hypertension News, Mayo Clinic holds a financial interest in the CorVista technology. They have stated any revenue supports their not-for-profit mission — but that context belongs in your evaluation, not buried in a footnote.

Clinical Applications: Where CorVista Fits in Your Practice

The patients most likely to benefit from CorVista are already in your waiting room. Pulmonary hypertension affects up to 10% of people over age 65, and according to CorVista Health, more than 500,000 Americans are estimated to be living with PH — many undiagnosed.

The diagnostic bottleneck is real and quantified. According to a peer-reviewed study published in PMC/Pulmonary Circulation, the median time from chronic unexplained dyspnea to PAH diagnosis was 2.26 years — involving an average of 3 echocardiograms, 6 specialist visits, and 2 hospitalizations per patient.

CorVista fits naturally into practices seeing:

• Symptomatic patients with repeated TTE-negative results
• Patients with unexplained dyspnea, especially older adults with comorbidities
• High-volume cardiology or pulmonology referral pipelines

On the workflow side, the signal capture takes approximately 3.5 minutes with the patient at rest, requires no fasting or radiation, and delivers results within a single visit — no specialist required to operate the device.

This is not a technology chasing a use case. It fills a documented gap in standard-of-care screening.

Evaluating CorVista for Your Practice: What to Consider Before You Decide

Before any adoption conversation starts, know what you are actually evaluating. This is not a capital equipment decision — the CorVista System requires no fasting, radiation, or specialist operation, and delivers results in under 30 minutes from a 3.5-minute signal capture with the patient at rest.

The practical checklist most administrators need:

• Workflow fit: Single-visit, non-invasive capture integrates into existing ambulatory cardiology or primary care workflows without dedicated staffing or facility upgrades
• Staff training: No specialist required to operate the device
• Reimbursement landscape: Worth a direct conversation with CorVista — coding pathways for AI-assisted diagnostics are evolving and practice-specific
• Internal case for adoption: A peer-reviewed PMC/Pulmonary Circulation study found the average PAH patient accumulates 3 echocardiograms, 6 specialist visits, and 2 hospitalizations before diagnosis — that is a quantifiable downstream cost your current workflow is already absorbing

One transparency note worth flagging: according to Pulmonary Hypertension News, Mayo Clinic holds a financial interest in the CorVista technology. Factor that into how you weigh the partnership as an independent validation signal.

The evidence trail behind CorVista is not theoretical — it is peer-reviewed, FDA-validated, and now anchored to one of the most scrutinized research institutions in the world. That is a meaningful distinction in a market flooded with AI diagnostic tools that have cleared regulatory hurdles but never faced institutional co-validation.

For the right practice, this is a low-risk entry point into an expanding diagnostic platform. The CorVista System delivers multi-condition cardiovascular results in under 30 minutes, with a 3.5-minute non-invasive signal capture requiring no fasting, no radiation, and no specialist to operate it — according to CorVista Health via Globe Newswire. That is a workflow addition most practices can absorb without structural disruption.

And this platform is not standing still. According to Globe Newswire, preliminary data from ACC.25 showed CorVista's investigational HFpEF algorithm achieved a diagnostic odds ratio of 29 for detecting heart failure. Practices adopting now are investing in a multi-condition cardiovascular diagnostic layer, not a single-use device.

If you are evaluating whether CorVista fits your practice's diagnostic workflow, the next step is a direct conversation with the people who can show you the clinical and operational specifics. Contact Perfect Rhythm today to request a product demo, clinical overview, or discuss how CorVista integrates with your practice's diagnostic workflow.

Frequently Asked Questions

What is the CorVista System and what does it diagnose?

The CorVista System is an FDA-cleared, non-invasive point-of-care diagnostic platform that uses machine learning to evaluate patients for coronary artery disease (CAD) and pulmonary hypertension (PH). It captures physiologic signals in approximately 3.5 minutes with the patient at rest and requires no fasting, radiation, or specialist operation.

What is the nature of the Mayo Clinic and CorVista collaboration?

According to Business Wire, CorVista Health announced a prospective observational research collaboration with Mayo Clinic on April 28, 2026, to evaluate whether the CorVista-PH test improves detection and referral of patients with suspected pulmonary hypertension alongside current standard diagnostic approaches. Mayo Clinic holds a financial interest in the technology, with any revenue directed toward its not-for-profit mission.

How accurate is the CorVista PH test?

The IDENTIFY PH validation study, published in the European Respiratory Journal in May 2025, showed the CorVista PH algorithm achieved 82% sensitivity, 92% specificity, and a negative predictive value greater than 99% across 462 symptomatic patients at 18 U.S. clinical sites. Performance was consistent across sex, age, BMI, and comorbidities including diabetes and COPD.

How does CorVista integrate into an existing clinical workflow?

The system requires no significant capital infrastructure, no specialist to operate, and delivers results within a single clinical visit under 30 minutes. It is designed to function alongside existing diagnostic tools — including echocardiography — rather than replacing them.

Why does early PH diagnosis matter clinically?

A retrospective study based on Mayo Clinic EHR data, published in Pulmonary Circulation in December 2025, found that 73% of patients in the early PH diagnosis group were alive at five years, compared to only 31% in the delayed diagnosis group. The current standard screening tool — transthoracic echocardiography — fails to visualize a key diagnostic marker in up to 41% of patients, according to Globe Newswire and JACC.